August 21, 2025
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
At Terns, we start with de-risked, clinically validated mechanisms of action and then boldly innovate, aiming to accelerate the development of superior, life-changing small molecule therapies for indications with serious unmet medical needs – all in service of our ultimate goal:
elevating human health.
pipeline
Our robust clinical-stage pipeline features differentiated small molecule assets targeting oncology and metabolic diseases.
DISCOVER OUR PIPELINE
clinical trials
We’re rapidly advancing clinical programs that matter. We currently have two active studies: CARDINAL for chronic myeloid leukemia (currently enrolling) and FALCON for obesity (fully enrolled).
EXPLORE CLINICAL TRIALS
careers
Our success is built upon exceptional talent. We’re committed to attracting and retaining world-class experts who thrive in our nimble, purpose-driven environment. Join our smart, motivated, experienced team of dedicated scientists and professionals working to have an enduring impact on human health.
VIEW OPEN POSITIONS